SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc.
Your view on SABSW
Overview
What the company does, where it operates, and who runs it.
About SAB Biotherapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Samuel J. Reich
- Headquarters
- 777 W 41st St., Miami Beach, FL, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Samuel J. Reich
- Headquarters
- 777 W 41st St., Miami Beach, FL, US
SAB Biotherapeutics, Inc. is a biopharmaceutical firm specializing in the development of immunotherapies. Their efforts are directed towards combating various health challenges, such as infectious and autoimmune diseases, as well as oncology.
Among their notable therapeutic candidates are SAB-142, an anti-thymocyte globulin intended for Type 1 diabetes; SAB-176, which targets seasonal influenza; and SAB-301, developed to counter Middle East Respiratory Syndrome Coronavirus (MERS-COV).
Founded in 2014, the company's headquarters are located in Sioux Falls, South Dakota, with a secondary office situated in Cambridge, Massachusetts.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for SAB Biotherapeutics, Inc. from FRC's valuation model, read against the market price. SABSW last traded at $0.0011; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for SAB Biotherapeutics, Inc.. Starting points for SAB Biotherapeutics, Inc.: EPS -$0.86, beta 0.53 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for SAB Biotherapeutics, Inc.. SAB Biotherapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for SAB Biotherapeutics, Inc.. Trailing twelve-month EPS for SAB Biotherapeutics, Inc. stands at -$0.86. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Analyst Ratings
- Strong Buy0
- Buy3
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.27 | -$0.22 | -$1.21 | -$0.80 |
| Low estimate | -$0.27 | -$0.22 | -$1.21 | -$0.80 |
| High estimate | -$0.27 | -$0.22 | -$1.21 | -$0.80 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | -$0.81 | -$0.35 | -$0.79 | — |
| Growth | +67.0% | +37.2% | -53.6% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $125000.00 | $0.00 | $333333.00 | $50000.00 |
| Low estimate | $125000.00 | $0.00 | $333333.00 | $50000.00 |
| High estimate | $125000.00 | $0.00 | $333333.00 | $50000.00 |
| No. of analysts | 1 | 0 | 5 | 8 |
| Year-ago revenue | $0.00 | $0.00 | $0.00 | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 13, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for SAB Biotherapeutics, Inc.. SAB Biotherapeutics, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
SAB Biotherapeutics, Inc. valued side by side against its closest peers. SAB Biotherapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold SAB Biotherapeutics, Inc., and how their positions are changing. At a $10,514 market value, institutional positions materially move SAB Biotherapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by SAB Biotherapeutics, Inc. executives and directors. Shares of SAB Biotherapeutics, Inc. have traded between $0.01 and $0.05 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for SAB Biotherapeutics, Inc.. Coverage tracks SAB Biotherapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of SAB Biotherapeutics, Inc.